New York, NY, March 22, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces it will exhibit for the first time at the American Association of Heart Failure Nurses Advanced Heart Failure Symposium, a medical education and medical technology exhibition held on March 23th and 24th in Philadelphia, PA.
The two-day symposium will serve to educate registered nurses and nurse practitioners about the latest advances in treatment recommendations and therapeutic and diagnostic technologies for advanced heart failure patients.
Daxor CEO Michael Feldschuh stated, “We are excited for two days of focused meetings with leaders in the area of advanced heart failure. Our participation in this exhibition is a direct response to a trend we have noticed in recent years towards holistic care teams composed of specialist and generalist clinicians, including and often managed by heart failure coordinator RNs and NPs. Being on the front line of a very difficult disease, these nurses are often best positioned to understand the positive impact Daxor’s precision blood volume analysis test has on patient care and outcomes.”
Per its website the AAHFN is an organization “dedicated to advancing nursing education, clinical practice and research to improve heart failure patient outcomes” with the “goal of setting the standards for heart failure nursing care.” The organization has held a meeting annually since 2004.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.